Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria

C. Van Malderen; J.P. Van geertruyden; S. Machevo; R. Gonzalez; Q. Bassat; A. Talisuna; A. Yeka; C. Nabasumba; P. Piola; A. Daniel; E. Turyakira; Pascale Forret; C. Van Overmeir; H. van Loen; A. Robert; Umberto D'Alessandro

doi:10.1186/1475-2875-11-139

Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria

C. Van Malderen
, J.P. Van geertruyden
, S. Machevo
, R. Gonzalez
, Q. Bassat
, A. Talisuna
, A. Yeka
, C. Nabasumba
, P. Piola
, A. Daniel
, E. Turyakira
, Pascale Forret
, C. Van Overmeir
, H. van Loen
, A. Robert
, Umberto D'Alessandro

Clinical Trial Centre

Research output: Contribution to journal › A1: Web of Science-article › peer-review

57 Downloads (Pure)

Abstract

BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children

Original language	English
Article number	139
Journal	Malaria Journal
Volume	11
Pages (from-to)	1-7
Number of pages	7
ISSN	1475-2875
DOIs	https://doi.org/10.1186/1475-2875-11-139
Publication status	Published - 2012

Keywords

Protozoal diseases
Malaria
Plasmodium falciparum
Vectors
Mosquitoes
Anopheles
Treatment
Artemisinin combination therapies (ACT)
Chlorproguanil
Dapsone
Artesunate
Children
Hemoglobin
Risk factors
G6PD deficiency
Randomized clinical trials
Africa-General
Author
PDF

Access to Document

10.1186/1475-2875-11-139Licence: CC BY

2012mjou0139Final published version, 230 KB

Cite this

Van Malderen, C., Van geertruyden, J. P., Machevo, S., Gonzalez, R., Bassat, Q., Talisuna, A., Yeka, A., Nabasumba, C., Piola, P., Daniel, A., Turyakira, E., Forret, P., Van Overmeir, C., van Loen, H., Robert, A., & D'Alessandro, U. (2012). Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria. Malaria Journal, 11, 1-7. Article 139. https://doi.org/10.1186/1475-2875-11-139

@article{7113072fbc3743f084ea497ff9ef6604,

title = "Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria",

abstract = "BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children ",

keywords = "Protozoal diseases, Malaria, Plasmodium falciparum, Vectors, Mosquitoes, Anopheles, Treatment, Artemisinin combination therapies (ACT), Chlorproguanil, Dapsone, Artesunate, Children, Hemoglobin, Risk factors, G6PD deficiency, Randomized clinical trials, Africa-General, Author, PDF",

author = "\{Van Malderen\}, C. and \{Van geertruyden\}, J.P. and S. Machevo and R. Gonzalez and Q. Bassat and A. Talisuna and A. Yeka and C. Nabasumba and P. Piola and A. Daniel and E. Turyakira and Pascale Forret and \{Van Overmeir\}, C. and \{van Loen\}, H. and A. Robert and Umberto D'Alessandro",

note = "ITG-B1B; ITG-B12B; ITG-B13B; ITG-C14B; ITG-BLA; MULTI; DBM; U-MALAR; DCS; U-CTU; JIF; E-only; DOI; PDF; Abstract; DSPACE",

year = "2012",

doi = "10.1186/1475-2875-11-139",

language = "English",

volume = "11",

pages = "1--7",

journal = "Malaria Journal",

issn = "1475-2875",

publisher = "BioMed Central",

}

Van Malderen, C, Van geertruyden, JP, Machevo, S, Gonzalez, R, Bassat, Q, Talisuna, A, Yeka, A, Nabasumba, C, Piola, P, Daniel, A, Turyakira, E, Forret, P, Van Overmeir, C, van Loen, H, Robert, A & D'Alessandro, U 2012, 'Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria', Malaria Journal, vol. 11, 139, pp. 1-7. https://doi.org/10.1186/1475-2875-11-139

TY - JOUR

T1 - Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria

AU - Van Malderen, C.

AU - Van geertruyden, J.P.

AU - Machevo, S.

AU - Gonzalez, R.

AU - Bassat, Q.

AU - Talisuna, A.

AU - Yeka, A.

AU - Nabasumba, C.

AU - Piola, P.

AU - Daniel, A.

AU - Turyakira, E.

AU - Forret, Pascale

AU - Van Overmeir, C.

AU - van Loen, H.

AU - Robert, A.

AU - D'Alessandro, Umberto

N1 - ITG-B1B; ITG-B12B; ITG-B13B; ITG-C14B; ITG-BLA; MULTI; DBM; U-MALAR; DCS; U-CTU; JIF; E-only; DOI; PDF; Abstract; DSPACE

PY - 2012

Y1 - 2012

N2 - BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children

AB - BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children

KW - Protozoal diseases

KW - Malaria

KW - Plasmodium falciparum

KW - Vectors

KW - Mosquitoes

KW - Anopheles

KW - Treatment

KW - Artemisinin combination therapies (ACT)

KW - Chlorproguanil

KW - Dapsone

KW - Artesunate

KW - Children

KW - Hemoglobin

KW - Risk factors

KW - G6PD deficiency

KW - Randomized clinical trials

KW - Africa-General

KW - Author

KW - PDF

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000306376200001

U2 - 10.1186/1475-2875-11-139

DO - 10.1186/1475-2875-11-139

M3 - A1: Web of Science-article

C2 - 22546009

SN - 1475-2875

VL - 11

SP - 1

EP - 7

JO - Malaria Journal

JF - Malaria Journal

M1 - 139

ER -

Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this